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Abstract
Though heart failure therapies, particularly for systolic heart failure, have developed
rapidly and markedly during the past four decades, a need for additional relief persists
and is progressively being met. Two new drugs have been approved for marketing in the
United States within the past two years, and two other glucose lowering therapies for
diabetes appear to have efficacy for heart failure as well. In addition, device therapy for
heart failure has progressed markedly during the past 5 years, particularly in refinements
of the indications and applications of devices to minimize symptoms and hospitalizations
and to maximize survival. This chapter will outline these recent developments.
Keywords: cardiovascular pharmacology, cardiovascular devices, angiotensin recep‐
tor blocker neprilysin inhibitor (ARNI), heart rate slowing, glucagon‐like peptide re‐
ceptor agonist
1. Introduction
Heart failure affects almost 6 million Americans [1], of whom 1 million are hospitalized for heart
failure annually [2]. According to latest available data published in June 2016 in the National
Vital Statistics Report, in 2014 cardiovascular diseases were the leading causes of death in the
United States, responsible for 803,227 deaths of which 68,626 (8.5%) were related to heart failure
[3]. Recent therapeutic advances suggest the potential for important amelioration of these
outcomes when the new therapies are added to conventional modalities. In this chapter we will
review the recent data supporting the incorporation of these new therapies into clinical practice.
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2. Ivabradine
In April 2015, FDA approved ivabradine for reduction of heart failure hospitalizations for
patients with heart failure with reduced ejection fraction (HFrEF) [4].
Ivabradine selectively blocks sinoatrial nodal cell hyperpolarization‐activated cyclic nucleo‐
tide‐gated (HCN) channels and, consequently, blocks the resulting transmembrane current (If)
by entering and binding to a site in the channel pore from the intracellular side [5, 6]. In the
United States, it is currently indicated for reduction in heart failure hospitalizations in patients
with symptomatic chronic heart failure with ejection fraction ≤35% who are in sinus rhythm,
with heart rate ≥70 beats per minute who already are being treated with maximally tolerated
β‐blockade [7] (as well as other conventional drugs for HFrEF). The drug now is recommended
in the updated AHA‐ACC guidelines for treatment of patients with HFrEF (class IIa recom‐
mendation, level of evidence B‐R) [8]. In several other countries, the drug also is indicated for
reduction in mortality or heart failure hospitalizations in patients with HFrEF, and also to
prevent angina pectoris in symptomatic patients with chronic stable coronary artery disease
irrespective of heart failure.
Ivabradine is unique in that it targets the HCN channel subtype found predominantly in
sinoatrial nodal cells [9] and, thus, has little effect elsewhere in the heart or in other tissues
(though drug action on HCN channels in the retina, similar to those in the sinoatrial node, is
believed to underlie the side effect of visual phosphenes [flashing scotomata] reported in 3%
of patients in the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial
[SHIFT]). This locus of activity differs from that of β‐blockers, which also slow heart rate but
act wherever β‐receptors are present (e.g., in the ventricles, causing negative inotropy, in the
bronchi, causing bronchoconstriction, etc.) and from calcium channel blockers, the action of
which, in the heart and smooth muscle, can cause negative inotropy, hypotension, and
constipation. Ivabradine is a selective and specific inhibitor of the myocardial If, a current
involved in modulating the cardiac pacemaker current [10]. At therapeutic concentrations,
both in animals and humans, ivabradine does not affect any other cardiac channel or current
(including those involving Na+, K+, or Ca2+) [6].
To be active, ivabradine needs to penetrate the HCN channels; this requires appropriate
orientation of the channel components, which occurs when the channel is hyperpolarized to
[‐40 mV]. Thus, the relevant channels are hyperpolarization‐activated. As heart rate increases,
the time during which the channels are hyperpolarized, and thus open to ivabradine, increases.
Consequently, ivabradine‐mediated heart rate reduction is “use dependent,” i.e., it is more
pronounced as heart rate increases [9].
Dosage: The evidence‐based and recommended maximal dose of ivabradine is 7.5 mg twice
daily [11]; the recommended starting dose of 5 mg twice daily.
Clinical evidence: Evidence supporting the utility of ivabradine for HFrEF primarily derives
from SHIFT. The study was an event‐driven, multinational, randomized, double‐blinded,
parallel‐group trial in patients in sinus rhythm with heart rate ≥70 beats/min with moderate‐
to‐severe heart failure and left ventricular ejection fraction ≤35% [11].
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The study involved 6505 patients (53 of the original 6558 patients were censored for a major
protocol violation) from 677 centers in 37 countries. Participants were randomized to ivabra‐
dine titrated to a maximum of 7.5 mg twice daily or to matched placebo and were followed for
a median of 22.9 months and a maximum of 42 months [11, 13].
Study subjects were at least 18 years old (male and female) with symptomatically stable heart
failure (and drug therapy) for at least 4 weeks and a hospitalization for worsening heart failure
within the previous 12 months [11].
Treatment with ivabradine was associated with a placebo‐subtracted average reduction in
heart rate of 10.9 bpm at 1 month after randomization and 9.1 bpm at 1 year. The SHIFT primary
composite endpoint (cardiovascular death or first hospitalization for worsening heart failure)
was reduced by 18% (hazard ratio, 0.82 [95% CI, 0.75–0.90], p < 0.0001), driven primarily by
reduction in hospitalizations for worsening heart failure (26% reduction, hazard ration, 0.74
[95% CI, 0.66–0.83], p < 0.0001). Death from heart failure fell to 26% (hazard ratio, 0.74 [95% CI,
0.58–0.94], p = 0.014).
From 1 year onward, at least 70% of patients were at the target dose of ivabradine (7.5 mg twice
daily). By contrast, only 49% of the 6505 patients enrolled in the trial were able to reach at least
50% of evidence‐based target β‐blocker dose at baseline (90% were receiving at least some dose
of beta blocker) because of contraindications or poor tolerability [11].
Cardiovascular and all‐cause deaths were not significantly reduced by ivabradine [11], though,
numerically, a 9% reduction in cardiovascular death was observed in the ivabradine group.
(However, in Europe, the European Medicines Agency ordered a reanalysis of the data with
entry at heart rate ≥75 bpm. This analysis revealed significant reduction in mortality as well
as in hospitalizations. As a result, approval in Europe is for patients with symptomatic heart
failure and LVEF ≤35% in sinus rhythm with heart rate ≥75 bpm.)
Sudden cardiac death was not affected by ivabradine, perhaps because of the effect of the
background β‐blocker treatment, which, unlike ivabradine, has intrinsic electrophysiological
effects and is known to affect sudden cardiac death [11].
Postulated mechanisms of benefit from ivabradine‐mediated heart rate reduction include
decreased myocyte ischemia, improving the balance between myocardial oxygen (and energy)
supply and demand; this effect is attributable not only to reduction in demand but also to
increased supply caused by lengthening duration of diastole during which coronary flow
occurs, and lack of negative lusitropy (relaxation, an active process that is inhibited by ischemia
and also by beta blockade) reducing impedance to coronary flow relative to beta blockade [12];
other data suggest that use of the drug also increases endothelial cell proliferation, endothelial
nitric oxide synthase (eNOS) activity, and increased collateral function [13].
The most prominent adverse effects of ivabradine are excessive bradycardia [14–16], atrial
fibrillation [14, 15], and phosphenes (visual brightness in one portion of the visual field) [15,
16], and a small but significant increase in systolic blood pressure (the clinical importance of
which is not clear) [15]. In SHIFT, the drug was not studied in patients with acute decompen‐
sated heart failure and thus is not indicated for such patients, through recent data [17, 18]
Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure
http://dx.doi.org/10.5772/66284
5
suggest that beginning the drug early during a hospitalization for acute decompensated heart
failure is acceptably safe and is effective in lowering heart rate. The drug also is contraindicated
in patients with blood pressure less than 90/50 mmHg, and in the presence of sick sinus
syndrome, sinoatrial block, or third degree AV block, unless a functioning demand pacemaker
is present, and in patients with severe hepatic impairment or concomitant use of strong
cytochrome P450 3A4 (CYP3A4) inhibitors or enhancers (ivabradine is metabolized in the liver
by the P450 CYP 3A4 system). Because the target heart rate (supported by the SHIFT data [11])
is 50–60 bpm, the drug should not be given if the pretherapy heart rate already is ≤60 bpm;
also, ivabradine is contraindicated (because it would have no effect) in patients who are
pacemaker dependent (heart rate maintained exclusively by the pacemaker). Animal studies
indicate the potential for fetal cardiac malformations if given during pregnancy [15]; therefore,
its use is contraindicated during pregnancy and, if used in nonpregnant women of child‐
bearing age, effective contraception should be assured. At doses up to 10 mg BID, ivabradine
prolongs the uncorrected QT interval; however, when appropriately corrected for heart rate,
this increase does not exceed 2 ms, precluding direct proarrhythmic potential [16].
3. Sacubitril‐valsartan
In July 2015, a few months after approval of ivabradine, FDA approved sacubitril‐valsartan,
also for treatment of patients with HFrEF [19].
Sacubitril‐valsartan is a combination of an already approved angiotensin receptor blocker
(valsartan) and a neprilysin inhibitor (such combination drugs are now known as ARNIs).
Neprilysin is a neutral endopeptidase and plays an important role in pathogenesis of heart
failure and hypertension by catalyzing the degradation of endogenous vasoactive peptides,
such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C‐type natriuretic
peptide (CNP), endothelin‐1 (ET‐1), angiotensin II, and bradykinin [20]. Inhibition of neprily‐
sin raises blood concentrations of these vasoactive peptides, some of which have potentially
beneficial hemodynamic effects in patients with heart failure [20].
Inhibition of this neutral endopeptidase promotes sodium and water excretion by inhibiting
sodium reabsorption in the proximal and distal nephron [21], and can cause reduction in
systemic vascular resistance, pulmonary artery pressure, and pulmonary capillary wedge
pressure. Blockage of neprilysin is associated with arterial stiffness reduction, enhanced
endothelial function, and cardiac antihypertrophic and antifibrotic effects [13, 21]. Sacubitril‐
valsartan also has inhibitory actions on the renin‐angiotensin‐aldosterone system and sym‐
pathetic nervous system [13, 21].
FDA has approved marketing of the new ARNI for reduction in mortality and heart failure
hospitalizations in patients with chronic heart failure (NYHA Class II–IV) and at least
moderately subnormal ejection fraction (<40%) and the AHA‐ACC Updated Heart Failure
Guideline recommend its use for this indication [8, 22]. In patients with chronic symptomatic
HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI
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is guideline‐recommended to further reduce morbidity and mortality (strength of recommen‐
dation I and level of evidence B‐R) [8].
Dosage: The initial dose of 24/26 mg twice daily is recommended for patients not currently
taking an ACE inhibitor or an angiotensin II receptor blocker (ARB) and for patients previously
taking low doses of these agents. The dose can be doubled every 2–4 weeks, as tolerated, to
reach the target maintenance dose of 97/103 mg twice daily [22].
Clinical evidence: The evidence supporting the efficacy of this ARNI was shown in the
Prospective Comparison of ARNI With ACEi to Determine Impact on Global Mortality and
Morbidity in Heart Failure (PARADIGM‐HF) trial [23].
The study included 8442 randomized patients with chronic heart failure (NYHA Class II–IV)
and ejection fraction ≤40%. Patients received either a combination of valsartan and sacubitril
(200 mg [97/103 mg] twice daily) or the ACE inhibitor enalapril (10 mg twice daily) in addition
to other guidelines‐recommended therapy. The trial was stopped early due to highly signifi‐
cant benefit of sacubitril‐valsartan without excessive adversity.
The composite endpoint (cardiovascular death and heart failure hospitalizations) was reduced
by 20%, as were both components of this endpoint (CV death reduction: hazard ratio, 0.80 [95%
CI, 0.71–0.89] p < 0.001, heart failure hospitalizations reduction: hazard ratio, 0.79 [95% CI,
0.71–0.89] p < 0.001). Death from any cause also was reduced by sacubitril‐valsartan by 16% (p
< 0.001).
During PARADIGM‐HF most adverse events were more frequent on the already approved
enalapril than on the ARNI combination drug. Of those of greatest concern (hypotension, renal
insufficiency, angioedema, and hyperkalemia) only hypotension was significantly more
frequent with sacubitril‐valsartan, while angioedema, though more frequent with the combi‐
nation (and known to be a potential consequence of neprilysin inhibition), occurred relatively
infrequently [8, 22]. As a result of these findings, the combination is contraindicated in patients
with a history of angioedema. It is also contraindicated during pregnancy, and if an ACE
inhibitor has been administered within 36 hours of switching to the ARNI or if patients
currently are receiving ACE inhibitors or have diabetes and are taking aliskerin [22].
4. New antidiabetic medications (liraglutide and empagliflozin)
Recent studies have shown beneficial effects of prototypes of two new groups of antidiabetic
medications on cardiovascular events. Though results specifically for heart failure hospitali‐
zations were significantly improved only with empagliflozin and did not reach statistical
significance for liraglutide (studies of which had insufficient power to test the hypothesis that
such events are prevented), there was clear numerical HF event reduction in patients with
HFrEF with both drugs and, thus, inclusion in this chapter is appropriate.
Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) receptor agonist that enhances insulin
secretion. One trial randomized 9340 patients with type 2 diabetes (HbA1c ≥ 7.0%) and
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underlying cardiovascular disease (CAD, cerebrovascular disease, PVD, CKD of stage 3 or
greater, or chronic heart failure NYHA class II‐III) to liraglutide or placebo on appropriate
conventional background therapy [24]. The median time of exposure to liraglutide or placebo
was 3.5 years. Death from cardiovascular causes (hazard ratio, 0.78 [95% CI, 0.66–0.93], p =
0.007), hospitalization for heart failure (hazard ratio, 0.87 [95% CI, 0.73–1.05], p = 0.14), and
nonfatal myocardial infarction, nonfatal stroke, and death from any cause all were at least
numerically lower in patients receiving liraglutide than placebo.
However, another far smaller double‐blind, placebo‐controlled randomized trial including 300
patients with type 2 diabetes and established HFrEF who were recently hospitalized did not
reveal any beneficial effect of liraglutide [25]. The power of this trial was relatively low to find
a significant difference if it existed, precluding firm conclusions about the role of liraglutide for
HFrEF.
Another antidiabetic medication which may provide favorable effects on mortality and
morbidity in patients with heart failure is empagliflozin, an inhibitor of the sodium glucose
cotransporter‐2 (SGLT‐2), which enhances renal glucose excretion [26]. The placebo‐controlled
EMPA‐REG trial assessed the effects of empagliflozin on cardiovascular morbidity and
mortality in 7020 randomized patients with type 2 diabetes and established cardiovascular
disease during a median follow‐up of 3.1 years. Relative risk of cardiovascular death was
reduced by 38% (3.7% with empagliflozin vs. 5.9% with placebo, hazard ratio, 0.62 [95% CI,
0.49–0.77], p < 0.001). Also, relative risk of hospitalization for heart failure was reduced by 35%
(hazard ratio, 0.65 [95% CI, 0.50–0.85], p = 0.002). Death from any cause also was lower with
empagliflozin (hazard ratio, 0.68 [95% CI, 0.57–0.82], p < 0.001).
5. Recent advances in device therapy
5.1. Left ventricular assist devices
Left ventricular assist devices (LVAD) are indwelling electromechanical pumps used to
support cardiac function in patients with advanced heart failure. First successfully implanted
in 1966 [27], such “first‐generation” devices were limited by size and durability, were highly
thrombogenic, and frequently complicated by infection. The mechanical design generally
featured pulsatile displacement, analogous to the mechanism of pumping by the native heart
[28]. More recent models have featured continuous flow with small rotating “impellers”
moving blood forward. As a result, newer pumps are smaller and have no bearings (resulting
in less mechanical wear and tear and greater durability than older models). Though generally
introduced by thoracotomy and requiring a transcutaneous connection to an external gener‐
ator, newer iterations are sufficiently slim such that they can be introduced percutaneously
(the Impella device) via the femoral or axillary artery in the cardiac catheterization lab [29,
30]. Such percutaneously introduced devices have less pumping capacity than the more
conventional models.
The effectiveness of LVAD was assessed in the Randomized Evaluation of Mechanical Assis‐
tance for the Treatment of Congestive Heart Failure (REMATCH) trial in 2001. The study
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involved 140 patients with advanced heart failure and contraindications to heart transplanta‐
tion surgery. The trial revealed a LVAD associated 48% reduction in all‐cause death (the
primary endpoint) compared with medical therapy (relative risk, 0.52 [95% CI, 0.34–0.78], p =
0.001) [31].
In subsequent trials LVAD has reduced mortality and improved quality of life and functional
capacity in patients with advanced heart failure. LVADs enhance total cardiac output by
adding to that of the damaged native heart, potentially allowing myocardial recovery,
particularly in patients with cardiogenic shock [30–34].
LVAD implantation currently is approved by FDA as a bridge to cardiac transplantation and
also as “destination therapy” in selected patients for whom transplantation may not be feasible
or possible [35].
Adverse events associated with LVAD use include thrombosis and thromboembolization
(potentially leading to stroke), bleeding, and infection [31, 35].
5.2. Extracorporeal membrane oxygenators (ECMO)
ECMO devices enable extracorporeal circulation and physiologic gas exchange during acute
respiratory and/or cardiorespiratory failure.
Two types of ECMO have been developed: veno‐arterial extracorporeal membrane oxygena‐
tors (VA‐ECMO) and veno‐venous extracorporeal membrane oxygenators (VV‐ECMO). FDA
has approved application of VA‐ECMO for short‐term support in patients with refractory
cardiogenic shock who have an underlying potentially reversible condition, acute onset
refractory cardiogenic shock unresponsive to inotropes and/or intra‐aortic balloon pump
counterpulsation (IABP), and extracorporeal cardiopulmonary resuscitation (ECPR) [36].
Supporting data are case series from multiple countries [36–41]. In one study involving 45
patients with refractory cardiogenic shock, ECMO was associated with survival to hospital
discharge in 29% (13/45) versus the expected total absence of survival without ECMO [40]. In
another series, survival was achieved in 71% of patients with refractory cardiogenic failure
during severe septic shock [41].
ECMO‐associated adverse events include bleeding, infection, renal failure, liver failure, need
for blood transfusion, hematuria, pulmonary complications, and need for thoracotomy [36].
5.3. Cardiac resynchronization therapy (CRT)
More than 20 years of research has established the role of CRT in patients with systolic heart
failure and widened QRS complex. By the 1990s, a link emerged between electrical dyssyn‐
chrony and LV function, in which conduction disturbances result in an abnormally circuitous
and lengthy conduction pathway, wasted work, and a reduction in cardiac output [42].
Intraventricular systolic dyssynchrony refers to lack of normal coordination in the timing of
contraction between ventricular segments [43]. Dyssynchrony can be identified by multiple
imaging techniques [44]. The prevalence of dyssynchrony is directly related to QRS duration
Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure
http://dx.doi.org/10.5772/66284
9
and ventricular size and inversely related to left ventricular ejection fraction (LVEF) [43].
Prevalence of echocardiographically detectable dyssynchrony ranges from 27% in patients
with QRS duration <120 ms, to 89% in those with QRS duration >150 ms [45].
CRT is effected by placing a pacemaker lead in each ventricle and setting the pacemaker
generator to coordinate the stimuli to both ventricles, hence normalizing the contraction
pattern. Mortality and morbidity (as well as symptoms) are consistently reduced (and LVEF
and reverse remodeling improved) by CRT in patients with refractory HFrEF and prolonged
QRS interval who are on optimal medical therapy [46–55].
CRT has been most clearly effective when QRS duration is abnormal, generally ≥150 ms with
a left bundle branch block pattern, and when LVEF is ≤35%. However, recently, benefit for a
wider range of patients has been explored. In BLOCK‐HF, patients with HF symptoms, LVEF
<50% and high degree AV block, who would otherwise be treated with RV pacing, were
randomized to biventricular pacing versus RV pacing (patients who met the by then conven‐
tional more stringent CRT indications were excluded). CRT provided 26% reduction in the
primary composite endpoint of total mortality, urgent HF care, or progression of increase in
the LV end‐systolic volume index [56].
In the randomized, double‐blind LESSER‐EARTH trial CRT was evaluated in patients with
LVEF ≤35% and QRS <120 ms who failed to improve in clinical outcomes or LV reverse
remodeling on conventional therapy. Importantly, dyssynchrony, determined by an imaging
study, was not required for inclusion in the study. The trial was terminated prematurely due
to futility and safety concerns, suggesting that CRT can worsen or provoke dyssynchrony in
patients with little or no dyssynchrony [57].
EchoCRT carried this issue further by using rigorous imaging criteria to detect dyssynchrony
among patients with QRS duration ≤130 ms, thus including those with nominally normal QRS
duration (<120 ms) and those slightly higher, as well as HFrEF with LVEF ≤35%, LVED ≥55 mm
and stable, guidelines‐based pharmacological therapy [58]. Patients were randomized to CRT
or no CRT. The study was stopped early due to futility, and death from cardiovascular causes
was higher among patients who received CRT.
While normalizing conduction patterns alone can account for mechanical benefit, cellular and
molecular alterations seem likely to contribute. Molecular mechanisms are not fully under‐
stood but, in experimental studies, CRT is associated with homogenization of stress kinase
activity, potentially important in supporting contractile function, and reducing fibrosis [59].
CRT is also associated with decline in global apoptosis and enhanced cell‐survival signaling
[60, 61]. Biventricular pacing reduces interstitial remodeling [61]. TNF‐ɑ, which is not present
in normal myocardium, stimulates fibrosis and apoptosis and contributes to the progression
of heart failure by direct toxic effects [62] and is activated by mechanical stretch [63]. CRT
lowers LV TNF‐ɑ after 6 months of therapy [61].
CRT also alters mitochondrial proteins [64] and upregulates β‐1 receptors and adenylate
cyclase activity [65] and partially ameliorates prolongation of the action potential duration
(APD) selectively in the lateral wall [66].
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Current AHA/ACC practice guideline* suggest application of CRT as follows [66]:
5.3.1. Class I indications:
1. CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle‐
branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or
ambulatory IV symptoms on guideline‐directed medical therapy (GDMT). (Level of
Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).
5.3.2. Class IIa indications:
1. CRT can be useful for patients who have LVEF ≤35%, sinus rhythm, a non‐LBBB pattern
with a QRS duration ≥150ms, and NYHA class III/ambulatory class IV symptoms on
GDMT (Level of Evidence: A).
2. CRT can be useful for patients who have LVEF of 35% or less, sinus rhythm, LBBB with a
QRS duration of 120–149 ms, and NYHA class II, III, or ambulatory IV symptoms on
GDMT (Level of Evidence: B).
3. CRT can be useful in patients with AF and LVEF of 35% or less on GDMT if (a) the patient
requires ventricular pacing or otherwise meets CRT criteria and (b) atrioventricular nodal
ablation or pharmacological rate control will allow near 100% ventricular pacing with
CRT (Level of Evidence: B).
4. CRT can be useful for patients on GDMT who have LVEF of 35% or less and are undergoing
placement of a new or replacement device implantation with anticipated requirement for
significant (>40%) ventricular pacing (Level of Evidence: C).
5.3.3. Class IIb indications
1. CRT may be considered for patients who have LVEF of 35% or less, sinus rhythm, a non‐
LBBB pattern with QRS duration of 120–149 ms, and NYHA class III/ambulatory class IV
on GDMT (Level of Evidence: B).
2. CRT may be considered for patients who have LVEF of 35% or less, sinus rhythm, a non‐
LBBB pattern with a QRS duration of 150 ms or greater, and NYHA class II symptoms on
GDMT (Level of Evidence: B).
3. CRT may be considered for patients who have LVEF of 30% or less, ischemic etiology of
HF, sinus rhythm, LBBB with a QRS duration of 150 ms or greater, and NYHA class I
symptoms on GDMT (Level of Evidence: C).
*These guidelines were published before BLOCK‐HF and EchoCRT were published.
Use of CRT is associated with short‐ and long‐term adverse effects [46–58]. Most commonly
reported complications include coronary‐sinus dissection/perforation, lead dislodgement,
implantation site infection, hemo‐/pneumothorax, pericardial effusion/pericarditis, hemato‐
ma, pacing failure, atrial fibrillation, inappropriate device stimulation of tissue, and DVT.
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6. The future of therapy for heart failure
Future developments for heart failure therapy will focus on the major current deficiencies. For
example, heart failure with preserved ejection fraction (HFpEF) is now known to account or
approximately half the heart failure population, with the same 5‐year survival rate as HFrEF.
No life‐prolonging or hospitalization reducing therapy now exists for patients with HFpEF
though there has been a suggestion of possible benefit with spironolactone [67]. However,
despite early hope with calcium channel blockers, there are no therapies specifically to prevent
or reverse diastolic dysfunction or to prevent or reverse fibrosis, which may be important
pathophysiological underpinnings of HFpEF (though these problems may be affected by
therapies aiming at other cardiac functional targets). Both problems are under active drug
development but no solutions have yet emerged. With regard to fibrosis, study in valve disease
models [68] suggest that collagen, by far the predominant element of myocardial fibrous tissue,
may not be the most appropriate target for preventive therapy, but that noncollagen elements,
which can directly affect force transmission, may be the more appropriate targets. It is not clear
whether this finding in regurgitant valve diseases, in which the myocardium is responding to
extrinsic loading conditions, can be extrapolated to systolic heart failure in which intrinsic
metabolic abnormalities are pathophysiologically most important. Moreover, though systolic
function is importantly improved by several currently available therapies, drugs that specifi‐
cally improve intrinsic myocardial contractility without countervailing adverse effects still are
needed. One promising candidate is omecamtiv mecarbil [69], which enhances myosin cross‐
bridge formation and duration, thus increasing systolic ejection time, but without increasing
oxygen utilization. Others may follow. Finally, a major adjunct to the therapies, themselves, is
monitoring the effects of therapy to enable precise titration and maximize benefits [70].
Although beyond the scope of this chapter, it is clear that devices for remote monitoring are
gaining ever greater impact on therapeutic decisions and will continue to be developed.
7. Conclusions
Therapy for heart failure and, specifically, for systolic heart failure (HFrEF), has progressed
dramatically during the past 30 years. In addition to the use of diuretics to relieve volume
overloading and associated symptoms, which already was established, five different groups
of drugs and multiple devices have been developed and assessed in large randomized
controlled clinical trials. The most recent of these developments, an f‐current blocker to slow
heart rate and a neprilysin blocker to enhance blood concentrations of several vasoactive
substances, have added to the benefits on survival and hospitalization achieved by previously
developed drugs that are still in use. At the same time, use of some drugs that were used
conventionally before recent additions has diminished (e.g., digoxin), superseded by new
developments. Innovations in therapeutic devices for heart failure also have moved rapidly
though, over the past 5 years, the greatest advances have been in delineation of the appropriate
application of existing devices. Nonetheless, 6 million Americans have heart failure as this is
written and one million of them will be hospitalized this year. Therefore, research and
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development of therapeutics remain importantly needed, most particularly focused in several
areas. For example, no life‐prolonging therapies yet have been identified for HFpEF (which
affects half the heart failure population), no therapies specifically to mitigate diastolic dys‐
function are available and no therapies specifically preventing myocardial fibrosis have been
developed. Moreover, though systolic function is importantly improved by several currently
available therapies, drugs that specifically improve intrinsic myocardial contractility without
countervailing adverse effects still are needed. Thus, while the current therapeutic landscape
reveals far more effective treatments than in the past, new research and development for heart
failure therapeutics are greatly needed.
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